The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease and ulcerative colitis. Guselkumab is currently approved to treat ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its dual-acting IL-23 inhibitor Tremfya (guselkumab) in Crohn’s disease (CD) and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya, Janssen-Cilag Limited) for use in adults with Crohn’s disease and ulcerative colitis (UC).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with ...

Tremfya (guselkumab) – J&J’s follow-up to blockbuster IL-12 and IL-23 inhibitor Stelara (ustekinumab) – has been approved in the US for moderate-to-severe plaque psoriasis since 2017.

Tremfya (guselkumab) is also the only drug in the class to achieve clinical remission and endoscopic response at one year with a fully subcutaneous treatment regimen, according to the drugmaker.

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with Crohn’s disease, offering both IV and subcutaneous induction options.

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...